What the technology does
A humanised monoclonal antibody against the IL-25 receptor IL-17BR that shows activity in models of lung fibrosis, colitis and asthma
Affinities of <1nM, desirable biophysical properties for a therapeutic drug, potential for therapeutic benefits in multiple diseases involving type 2 immune responses
Main application field
Therapeutic – antibody
Patents granted in Japan (JP20120504066T), United States (US20130056559), Australia (AU20100233535), Europe (EP20100712110), China (CN201080022541) and Hong Kong (HK20120111452). Published in Canada (CA20102757104) and India (IN2011DN08006).
Collaboration or exclusive licence